What does this research mean for the field?

Anthracycline-based chemotherapy improves 10-year overall survival by 13.6% compared to non-anthracycline regimens in patients with metaplastic breast cancer. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

Assess survival differences between anthracycline-based and non-anthracycline-based chemotherapy for metaplastic breast cancer.

February 19, 2026

Abstract PS4-11-14: Anthracycline-based Systemic Chemotherapy on Long-term Prognosis of Metaplastic Breast Cancer: A Real World Study with 637 Cases in 14 multi-center

Key Points

Assess survival differences between anthracycline-based and non-anthracycline-based chemotherapy for metaplastic breast cancer.
Analyzed 637 cases of metaplastic breast cancer from 14 hospitals in China.
Conducted Kaplan-Meier analysis and Cox proportional hazards models.
Estimated survival effects and identified prognostic factors during 30 months of follow-up.
243 patients received anthracycline-based regimen, while 130 received non-anthracycline.
10-year overall survival improved by 13.6% in the anthracycline cohort compared to non-anthracycline.
Local-regional recurrence was lower in the anthracycline cohort (6.2%) than in the non-anthracycline cohort (13.1%).

Abstract

Abstract Background: The standard chemotherapy treatment regimen for metaplastic breast cancer (MpBC) remained uncertain. This study aimed to assess the survival disparities between anthracycline-based and non-anthracycline-based regimens and investigate appropriate chemo-regimen for MpBC patients in real world. Patients and Methods: A total of 637 cases with MpBC in admitting diagnosis between 2002 and 2025 were collected from 14 large hospitals in China. Kaplan- Meier analysis, univariate and multivariate Cox proportion hazard models, and cumulative incidence flow were performed to estimate survival effect and identify prognostic factors comprehensively during the median follow-up time of 30 months. Results: Among the 373 patients enrolled in final study, totally 243 (65.1%) patients received anthracycline-based regimen (anthracycline cohort) whereas 130 (34.9%) patients with non-anthracycline-based regimen (non-anthracycline cohort). Subjects in anthracycline cohort had an absolute improvement of 13.6% (89.4% vs. 75.8%) and 7.5% (82.9% vs. 75.9%) in 10-year overall survival (OS) and 10-year local-regional recurrence free survival (LRFS), respectively, in comparison with those in non-anthracycline cohort. And anthracycline-based regimen was found to be an independently favorable factor of OS through multivariate Cox analysis. The local-regional recurrence occurred in 6.2% (23/373) of patients, while 13.1% (49/373) of MpBC patients developed distant metastases. Conclusion: This multi-center study identified the association between administration of anthracycline and improved OS, anthracycline-based regimen had higher likelihood to be the preferred protocol for MpBC. Citation Format: C. Zhou, P. Ni, Z. Dai, G. Qiao, Y. Ren. Anthracycline-based Systemic Chemotherapy on Long-term Prognosis of Metaplastic Breast Cancer: A Real World Study with 637 Cases in 14 multi-center abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-11-14.

Bookmark

Cite This Study

Zhou et al. (Tue,) studied this question.

synapsesocial.com/papers/6996a83eecb39a600b3eeb96 https://doi.org/https://doi.org/10.1158/1557-3265.sabcs25-ps4-11-14

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark